VEGFA and amyotrophic lateral sclerosis: In a clinical study, Van Damme et al., showed that a detectable CSF level of VEGF in patients with ALS was achieved through daily ICV dosing of VEGF (2 mg/day), and the treatment was well tolerated in most patients [20].